PL1715865T3 - Środek do leczenia hiperlipemii zawierający pitawastatyny i kwas eikozapentaenowy - Google Patents

Środek do leczenia hiperlipemii zawierający pitawastatyny i kwas eikozapentaenowy

Info

Publication number: PL1715865T3
Authority: PL; Poland
Prior art keywords: therapeutic agent; eicosapentaenoic acid; pitavastatins; hyperlipemia therapeutic; hyperlipemia
Prior art date: 2004-02-19

Application number

PL05710692T

Other languages

English (en)

Inventor

Taro Aoki

Junji Yamaguchi

Yusuke Sasaki

Original Assignee

Kowa Co

Nissan Chemical Ind Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-19

Filing date

2005-02-18

Publication date

2010-09-30

2005-02-18 Application filed by Kowa Co, Nissan Chemical Ind Ltd filed Critical Kowa Co

2010-09-30 Publication of PL1715865T3 publication Critical patent/PL1715865T3/pl

Links

JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title abstract 3
229960005135 eicosapentaenoic acid Drugs 0.000 title abstract 3
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title abstract 3
235000020673 eicosapentaenoic acid Nutrition 0.000 title abstract 3
239000003814 drug Substances 0.000 title abstract 2
229940124597 therapeutic agent Drugs 0.000 title abstract 2
201000005577 familial hyperlipidemia Diseases 0.000 title 1
230000003247 decreasing effect Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 abstract 1
229960002797 pitavastatin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL05710692T 2004-02-19 2005-02-18 Środek do leczenia hiperlipemii zawierający pitawastatyny i kwas eikozapentaenowy PL1715865T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10/780,640 US7022713B2 (en)	2004-02-19	2004-02-19	Hyperlipemia therapeutic agent
EP05710692A EP1715865B9 (en)	2004-02-19	2005-02-18	Hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid
PCT/JP2005/003092 WO2005079797A2 (en)	2004-02-19	2005-02-18	Hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid

Publications (1)

Publication Number	Publication Date
PL1715865T3 true PL1715865T3 (pl)	2010-09-30

Family

ID=34860884

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05710692T PL1715865T3 (pl)	2004-02-19	2005-02-18	Środek do leczenia hiperlipemii zawierający pitawastatyny i kwas eikozapentaenowy

Country Status (14)

Country	Link
US (2)	US7022713B2 (pl)
EP (1)	EP1715865B9 (pl)
JP (1)	JP5474276B2 (pl)
KR (1)	KR101376449B1 (pl)
CN (1)	CN100475208C (pl)
AT (1)	ATE460164T1 (pl)
CY (1)	CY1110133T1 (pl)
DE (1)	DE602005019856D1 (pl)
DK (1)	DK1715865T3 (pl)
ES (1)	ES2342609T3 (pl)
PL (1)	PL1715865T3 (pl)
PT (1)	PT1715865E (pl)
SI (1)	SI1715865T1 (pl)
WO (1)	WO2005079797A2 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4719572B2 (ja) *	2003-04-17	2011-07-06	興和株式会社	Ｌｋｌｆ／ｋｌｆ２遺伝子発現促進剤
US7022713B2 (en) *	2004-02-19	2006-04-04	Kowa Co., Ltd.	Hyperlipemia therapeutic agent
JP5069448B2 (ja) *	2006-02-07	2012-11-07	持田製薬株式会社	脳卒中再発予防用組成物
BRPI0621313A2 (pt) *	2006-02-07	2011-12-06	Mochilda Pharmaceutical Co Ltd	composição para previnir recorrência de acidente vascular cerebral
US8784886B2 (en) *	2006-03-09	2014-07-22	GlaxoSmithKline, LLC	Coating capsules with active pharmaceutical ingredients
US7728697B2 (en) *	2006-09-26	2010-06-01	Mg Materials Corporation	Systems and methods for electrically reducing ferroelectric materials to increase bulk conductivity
US20080085911A1 (en) *	2006-10-10	2008-04-10	Reliant Pharmaceuticals, Inc.	Statin and omega-3 fatty acids for reduction of apo-b levels
US20100119600A1 (en) *	2007-06-01	2010-05-13	Joar Opheim	Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
KR20110039249A (ko) *	2008-07-07	2011-04-15	모치다 세이야쿠 가부시키가이샤	지질 이상증의 개선 또는 치료약
PL2334295T3 (pl)	2008-09-02	2017-12-29	Amarin Pharmaceuticals Ltd	Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
KR20140007973A (ko)	2009-02-10	2014-01-20	아마린 파마, 인크.	고중성지방혈증 치료 방법
CN104042617A (zh)	2009-04-29	2014-09-17	阿马里纳药物爱尔兰有限公司	含有epa和心血管剂的药物组合物以及使用其的方法
SG10201912687WA (en)	2009-04-29	2020-02-27	Amarin Pharmaceuticals Ie Ltd	Stable Pharmaceutical Composition And Methods Of Using Same
EP3698781A1 (en)	2009-06-15	2020-08-26	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid for treating myocardial infarction in a subject on concomitant statin therapy
RU2758369C2 (ru)	2009-09-23	2021-10-28	Амарин Фармасьютикалз Айрлэнд Лимитед	Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения
JP5951489B2 (ja) *	2009-10-16	2016-07-13	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅＬＬＣ	組成物
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en)	2010-11-29	2019-10-25	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en)	2011-11-07	2013-05-16	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US9827219B2 (en)	2012-01-06	2017-11-28	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
LT4338805T (lt)	2012-06-29	2025-09-25	Amarin Pharmaceuticals Ireland Limited	Eikozapentaeno rūgšties etilo esteris, skirtas panaudoti mažinant nemirtino miokardo infarkto riziką subjektui, gydomam statinais
CN102824636A (zh) *	2012-08-15	2012-12-19	四川大学	一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途
US20150265566A1 (en)	2012-11-06	2015-09-24	Amarin Pharmaceuticals Ireland Limited	Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9895332B2 (en)	2013-10-30	2018-02-20	Patheon Softgels, Inc.	Enteric soft capsules comprising polyunsaturated fatty acids
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
US10172818B2 (en)	2014-06-16	2019-01-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US9895333B2 (en)	2014-06-26	2018-02-20	Patheon Softgels Inc.	Enhanced bioavailability of polyunsaturated fatty acids
WO2015200563A1 (en) *	2014-06-26	2015-12-30	Banner Life Sciences Llc	Enhanced bioavailability of polysaturated fatty acids
WO2016026139A1 (zh) *	2014-08-22	2016-02-25	财团法人国防教育研究基金会	用于治疗非酒精性脂肪肝疾病的药物及应用
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10600502B2 (en)	2016-12-20	2020-03-24	Astrazeneca Uk Ltd.	Systems and methods for dispensing a statin medication over the counter
TW201900160A (zh)	2017-05-19	2019-01-01	愛爾蘭商艾瑪琳製藥愛爾蘭有限公司	用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3750535B1 (en)	2018-09-24	2025-12-31	Amarin Pharmaceuticals Ireland Limited	METHODS FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT
BR112022009189A2 (pt)	2019-11-12	2022-07-26	Amarin Pharmaceuticals Ie Ltd	Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
US20220008519A1 (en)	2020-07-09	2022-01-13	Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS)	Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
AU2022263358A1 (en)	2021-04-21	2023-11-30	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2569746B2 (ja) *	1987-08-20	1997-01-08	日産化学工業株式会社	キノリン系メバロノラクトン類
GB8819110D0 (en) *	1988-08-11	1988-09-14	Norsk Hydro As	Antihypertensive drug & method for production
US5861399A (en) *	1996-07-17	1999-01-19	Heart Care Partners	Methods and compositions for the rapid and enduring relief of inadequate myocardial function
CN1109543C (zh) *	1996-10-11	2003-05-28	斯卡里斯塔有限公司	包括二十碳五烯酸和/或十八碳四烯酸的药物制剂
US6083497A (en) *	1997-11-05	2000-07-04	Geltex Pharmaceuticals, Inc.	Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6777552B2 (en) *	2001-08-16	2004-08-17	Teva Pharmaceutical Industries, Ltd.	Processes for preparing calcium salt forms of statins
US6982251B2 (en) *	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
CN1370544A (zh) *	2001-02-27	2002-09-25	张洪超	一种具有降血脂作用的林蛙卵油营养保健胶囊及其制法
EP1425287A4 (en) *	2001-08-16	2005-09-07	Teva Pharma	PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINES
CN1197564C (zh) *	2001-09-30	2005-04-20	中国药品生物制品检定所	海狗油在制备治疗脂代谢紊乱药物中的应用
EP1534243A4 (en) *	2002-08-26	2008-08-13	Lipid Sciences Inc	TREATMENT OF ALZHEIMER WITH ENTLIPIDED PROTEIN PARTICLES
US7022713B2 (en) *	2004-02-19	2006-04-04	Kowa Co., Ltd.	Hyperlipemia therapeutic agent

2004
- 2004-02-19 US US10/780,640 patent/US7022713B2/en not_active Expired - Lifetime
2005
- 2005-02-18 KR KR1020067016099A patent/KR101376449B1/ko not_active Expired - Fee Related
- 2005-02-18 CN CNB2005800053563A patent/CN100475208C/zh not_active Expired - Fee Related
- 2005-02-18 SI SI200531022T patent/SI1715865T1/sl unknown
- 2005-02-18 EP EP05710692A patent/EP1715865B9/en not_active Expired - Lifetime
- 2005-02-18 AT AT05710692T patent/ATE460164T1/de active
- 2005-02-18 DE DE602005019856T patent/DE602005019856D1/de not_active Expired - Lifetime
- 2005-02-18 DK DK05710692.4T patent/DK1715865T3/da active
- 2005-02-18 WO PCT/JP2005/003092 patent/WO2005079797A2/en not_active Ceased
- 2005-02-18 JP JP2006525561A patent/JP5474276B2/ja not_active Expired - Fee Related
- 2005-02-18 ES ES05710692T patent/ES2342609T3/es not_active Expired - Lifetime
- 2005-02-18 PL PL05710692T patent/PL1715865T3/pl unknown
- 2005-02-18 PT PT05710692T patent/PT1715865E/pt unknown
- 2005-12-05 US US11/293,217 patent/US7776881B2/en not_active Expired - Fee Related
2010
- 2010-06-03 CY CY20101100490T patent/CY1110133T1/el unknown

Also Published As

Publication number	Publication date
CN100475208C (zh)	2009-04-08
CY1110133T1 (el)	2015-01-14
EP1715865A2 (en)	2006-11-02
EP1715865B1 (en)	2010-03-10
EP1715865B8 (en)	2010-05-19
ATE460164T1 (de)	2010-03-15
KR101376449B1 (ko)	2014-03-19
CN1921860A (zh)	2007-02-28
JP2007523049A (ja)	2007-08-16
KR20060109988A (ko)	2006-10-23
DE602005019856D1 (de)	2010-04-22
DK1715865T3 (da)	2010-05-10
JP5474276B2 (ja)	2014-04-16
US7022713B2 (en)	2006-04-04
WO2005079797A3 (en)	2006-05-11
HK1098953A1 (zh)	2007-08-03
PT1715865E (pt)	2010-04-01
SI1715865T1 (sl)	2010-08-31
WO2005079797A2 (en)	2005-09-01
US20050187292A1 (en)	2005-08-25
US20060111437A1 (en)	2006-05-25
US7776881B2 (en)	2010-08-17
EP1715865B9 (en)	2010-12-15
ES2342609T3 (es)	2010-07-09

Publication	Publication Date	Title
SI1715865T1 (sl)	2010-08-31	Terapevtsko sredstvo proti hiperlilpidemiji, ki obsega pitavastatine in eikozapentanojsko kislino
EP1750730A4 (en)	2008-01-09	TREATMENT OF HYPERCHOLESTERINEMIA, HYPERTRIGLYCERIDEMIA, AND HEART CIRCUIT-RELATED TREATMENTS USING PHOSPHALIPASE A2 INHIBITORS
AU2016204344A1 (en)	2016-07-14	Improved methods and compositions for wound healing
UA89220C2 (ru)	2010-01-11	Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы
WO2010011585A3 (en)	2011-04-07	Ophthalmic device having therapeutic agent delivery capability and method of forming same
MX349787B (es)	2017-08-11	Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
EP2813223B8 (en)	2018-03-07	Metal delivery agents and therapeutic uses of the same
WO2005048923A3 (en)	2006-08-17	Extended release venlafaxine formulation
SG10201504425SA (en)	2015-07-30	Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
EP1880719A3 (en)	2008-02-20	Composition for prophylaxis or treatment of urinary system infection and method thereof
WO2007041398A3 (en)	2007-12-27	Treatment of cancer with specific rxr agonists
MX2008000915A (es)	2008-04-04	Tratamiento con inhibidores de absorcion de colesterol basados en azetidinona y acidos grasos omega-3 y un producto de combinacion de los mismos.
NZ602571A (en)	2014-03-28	Micrornas that regulate muscle cell proliferation and differentiation
IL180739A0 (en)	2007-06-03	Novel fenofibrate formulations and related methods of treatment
EP2073752A4 (en)	2014-03-12	IMPLANTABLE DEVICES FOR THE TREATMENT OF INCONTINENCE, AND METHODS OF USE
IL189162A0 (en)	2008-08-07	Use of hydroxybenzoic acid ester and analogues for the manufacture of a medicament for the prevention and treatment of virus infection
WO2009067856A8 (zh)	2010-06-03	组蛋白去乙酰化酶抑制剂及其制备和用途
AP2005003227A0 (en)	2005-03-31	Synergistic combination of an alpha-2-delta ligandand a PDEV inhibitor for use in the treatment of pain.
TW200638950A (en)	2006-11-16	Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
WO2003057205A3 (de)	2004-04-01	KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL
MX2007006279A (es)	2007-06-14	Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa.
WO2007130419A3 (en)	2008-12-11	Histone deacetylase inhibitors for the treatment of neurodegeneration
WO2008027880A3 (en)	2008-12-31	Strontium-based treatment of otosclerosis
ZA200701917B (en)	2008-06-25	Novel fenofibrate formulations and related methods of treatment
WO2007077454A3 (en)	2007-08-30	A therapeutic composition comprising an inhibitor of an hsp 90 protein